title: Pharmacoutilization of statin therapy after acute myocardial infarction. A real practice analysis based on administrative data.
abstract: BACKGROUND
  Despite randomized and controlled trials indicating continuous treatment with statin therapy as a factor in reducing morbidity and mortality after acute myocardial infarction, records reveal a high percentage of patients at risk who are either not receiving treatment or being treated inadequately.
  
  
  METHODS
  An administrative database kept by the Local Health Unit of Ravenna and listing patient baseline characteristics, drug prescriptions and hospital admissions was used to perform: 1) an analysis of patients discharged alive from hospital each year between 1996 and 2000 with a diagnosis of acute myocardial infarction, and 2) a retrospective cohort study of drug utilization, and particularly the use of statins, year by year. All prescriptions for statins filled in the 6 months after hospital discharge were considered and used to classify patients in terms of their exposure to statin therapy and of their pharmacoutilization.
  
  
  RESULTS
  A total of 2265 subjects were enrolled (446 in 1996, 440 in 1997, 443 in 1998, 443 in 1999, and 493 in 2000). The percentage of patients treated with statins increased each year (from 22.6% in 1996 to 43.8% in 2000) as did the percentage of adequately dosed patients (from 4.3% in 1996 to 23.9% in 2000). The overall cost of dispensed statins amounted to 10,610 euros in 1996 and 45,102 euros in 2000. The proportion of cost for statins accountable to adequately dosed patients ranged from 36.4% in 1996 to 77.4% in 2000. The average cost per adequately dosed patient ranged from 203.40 euros in 1996 to 296.00 euros in 2000 and increased year by year.
  
  
  CONCLUSIONS
  Pharmacoutilization of statin therapy was found to be unsatisfactory in each study year. Interestingly, however, the trend indicated by the study suggests increasing percentages of patients being exposed to the treatment, and of adequately dosed patients. These results may be attributed to a greater awareness of the need for proper treatment, and may be considered as reflecting a significant improvement in drug management.
authors.affiliation: CliCol Srl-Health, Economics and Outcomes Research, Ravenna, Italy. luca.degliesposti@clicon.it
authors.forename: Luca
authors.initials: L
authors.lastname: Degli Esposti
authors.forename: Mirko
authors.initials: M
authors.lastname: Di Martino
authors.forename: Stefania
authors.initials: S
authors.lastname: Saragoni
authors.forename: Giorgia
authors.initials: G
authors.lastname: Valpiani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Capone
authors.forename: Elena
authors.initials: E
authors.lastname: Corvi
authors.forename: Ezio
authors.initials: E
authors.lastname: Degli Esposti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003361:Cost Allocation / Q000639:trends; D004305:Dose-Response Relationship, Drug; D004358:Drug Therapy / Q000191:economics / Q000639:trends; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000191:economics; D010343:Patient Admission; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors